<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04806607</url>
  </required_header>
  <id_info>
    <org_study_id>2020-1072</org_study_id>
    <nct_id>NCT04806607</nct_id>
  </id_info>
  <brief_title>19Gauge Fine Needle Biopsy (FNB) Versus 22Gauge FNB for Endoscopic Ultrasound Guided Liver Biopsy (EUS-LB)</brief_title>
  <official_title>19Gauge Fine Needle Biopsy (FNB) Versus 22Gauge FNB for Endoscopic Ultrasound Guided Liver Biopsy (EUS-LB): A Randomized Prospective Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Geisinger Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Geisinger Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the adequacy of EUS-LB using a 19G core needle compared to a 22G core needle in&#xD;
      a prospective randomized study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The 19Gauge core and 22Gauge core needles have both been used for EUS-LB with good success.&#xD;
      Previous studies have reported good safety and tissue adequacy with both the needles, but the&#xD;
      head-on comparison between these two needles is lacking.&#xD;
&#xD;
      This is a prospective randomized trial comparing the biopsy specimen adequacy of 19Gauge&#xD;
      versus 22Gauge core needles for EUS-LB.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 30, 2021</start_date>
  <completion_date type="Anticipated">March 29, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is a prospective randomized trial comparing the biopsy specimen adequacy of 19G versus 22G core needles in subjects undergoing an EUS-LB.</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Length of Longest Piece</measure>
    <time_frame>Up to 5 Days</time_frame>
    <description>Length of the longest piece of the liver tissue obtained</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Aggregate Specimen Length</measure>
    <time_frame>3 to 5 Days</time_frame>
    <description>Cumulative length of all the pieces of tissue obtained</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Degree of Fragmentation</measure>
    <time_frame>3 to 5 Days</time_frame>
    <description>Size of the fragments of the samples will be measured, then classified as small (&lt;5 mm), medium (5-8 mm) or large (&gt;8 mm), then compared for the 2 needles</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Portal Tracts in the Specimen</measure>
    <time_frame>3 to 5 Days</time_frame>
    <description>Number of portal triads will be counted in the specimens and compared for the 2 needles</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events and Serious Adverse Events</measure>
    <time_frame>7 to 10 Days Post Procedure</time_frame>
    <description>Untoward, undesired, or unplanned event</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Chronic Liver Disease</condition>
  <arm_group>
    <arm_group_label>19Gauge Fine Needle Biopsy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>19Gauge Fine Needle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>22 Gauge Fine Needle Biopsy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>22Gauge Fine Needle</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>19G FNB</intervention_name>
    <description>Biopsy specimen adequacy using the 19G FNB</description>
    <arm_group_label>19Gauge Fine Needle Biopsy</arm_group_label>
    <arm_group_label>22 Gauge Fine Needle Biopsy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>22G FNB</intervention_name>
    <description>Biopsy specimen adequacy using the 22G FNB.</description>
    <arm_group_label>19Gauge Fine Needle Biopsy</arm_group_label>
    <arm_group_label>22 Gauge Fine Needle Biopsy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients undergoing EUS-LB&#xD;
&#xD;
          -  Platelet Count &gt; 50,000&#xD;
&#xD;
          -  International normalized ratio (INR) &lt; 1.5&#xD;
&#xD;
          -  Age &gt; 18 years of age&#xD;
&#xD;
          -  Non-Pregnant Patients&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt; 18 Years of Age&#xD;
&#xD;
          -  Pregnant Patients&#xD;
&#xD;
          -  Inability to obtain consent&#xD;
&#xD;
          -  Anticoagulants or anti-platelet agents (excluding aspirin) within the last 7 -10 days&#xD;
&#xD;
          -  Platelet count &lt; 50,000&#xD;
&#xD;
          -  Presence of Ascites&#xD;
&#xD;
          -  Known Liver Cirrhosis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David L Diehl, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Geisinger Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>S Vikas Kumar, MD</last_name>
    <phone>570-271-6405</phone>
    <email>vkumar3@geisinger.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kelly Haddock, MBA</last_name>
    <phone>570-214-4945</phone>
    <email>kmhaddock@geisinger.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Geisinger Medical Center</name>
      <address>
        <city>Danville</city>
        <state>Pennsylvania</state>
        <zip>17822</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David L Diehl, MD</last_name>
      <phone>570-271-6405</phone>
      <email>dldiehl@geisinger.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kelly Haddock, MBA</last_name>
      <phone>570-214-4945</phone>
      <email>kmhaddock@geisinger.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Vikas Kumar, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>March 17, 2021</study_first_submitted>
  <study_first_submitted_qc>March 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 19, 2021</study_first_posted>
  <last_update_submitted>November 15, 2021</last_update_submitted>
  <last_update_submitted_qc>November 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Geisinger Clinic</investigator_affiliation>
    <investigator_full_name>David L. Diehl</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

